Molecular imaging of EGFR: It's time to go beyond receptor expression

Journal of Nuclear Medicine

Volumn 50, Issue 7, 2009, Pages 1195-1196

  Pantaleo, Maria A ^a   Nannini, Margherita ^a   Fanti, Stefano ^a   Boschi, Stefano ^a   Lollini, Pier Luigi ^a   Biasco, Guido ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB C 11; PD153035 C 11; PROTEIN TYROSINE KINASE INHIBITOR; RADIOISOTOPE; UNCLASSIFIED DRUG;

CLINICAL PRACTICE; DOSIMETRY; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MEDICINE; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UTERINE CERVIX CARCINOMA;

ADULT; CARBON RADIOISOTOPES; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LIGANDS; LUNG NEOPLASMS; MALE; METABOLIC CLEARANCE RATE; MOLECULAR PROBE TECHNIQUES; POSITRON-EMISSION TOMOGRAPHY; QUINAZOLINES; RADIOMETRY; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 67650033111     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.063909     Document Type: Letter

References (16)

1. 11C-PD153035 in humans. J Nucl Med. 2009;50:303-308.
2. Tolmachev V, Friedman M, Sandström M, et al. Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry. J Nucl Med. 2009;50:274-283.
3. 11C-labeled PD153035 in rats without and with neuroblastoma implants. Life Sci. 1999;65:165-174.
4. Wang H, Yu J, Yang G, et al. Assessment of 11C-labeled-4-N-(3- bromoanilino)-6,7-dimethoxyquinazoline as a positron emission tomography agent to monitor epidermal growth factor receptor expression. Cancer Sci. 2007;98:1413-1416.
5. Bonasera TA, Ortu G, Rozen Y, et al. Potential 18F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase. Nucl Med Biol. 2001;28:359-374.
6. Tolmachev V, Nilsson FY, Widström C, et al. 111In-benzyl-DTPA-ZHER2: 342, an Affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med. 2006;47:846-853.
7. Pantaleo MA, Nannini M, Maleddu A, et al. Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. Ann Oncol. 2009;20:213-226.
8. Mishani E, Abourbeh G, Eiblmaier M, Anderson CJ. Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. Curr Pharm Des. 2008;14:2983-2998.
9. Gelovani JG. Molecular imaging of epidermal growth factor receptor expression-activity at the kinase level in tumors with positron emission tomography. Cancer Metastasis Rev. 2008;27:645-653.
10. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
11. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500.
12. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to antiepidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27:2091-2096.
13. 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol. 2006;8:262-277.
14. 11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. Cancer Res. 2009;69:873-878.
15. Kancha RK, von Bubnoff N, Peschel C, Duyster J. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Clin Cancer Res. 2009;15:460-467.
16. Pantaleo MA, Fanti S, Nannini M, et al. What oncologists need and require from nuclear medicine. Eur J Nucl Med Mol Imaging. 2008;35:1761-1765.